Role of Oxidized LDL and Antioxidants in Atherosclerosis

  • Daniel Steinberg
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 369)


Atherosclerosis is responsible for more morbidity and mortality than any other single degenerative disease, including cancer. Its clinical expression in the form of myocardial infarction, stroke and peripheral vascular disease accounts for about 50% of all deaths in developed countries. It is a disease of aging, in the sense that the occurrence of clinically significant lesions increases sharply past the 5th decade, but it is equally clear that clinical expression is strongly linked to a number of environmental factors (e.g., hypercholesterolemia, hypertension, cigarette smoking, etc.). Correction of these “risk factors”, especially hypercholesterolemia, has clearly been shown to reduce the number of clinical events. An important point that is often overlooked is that spontaneous atherosclerosis in animals, including non-human primates, is very rare. This stands in contrast to the very significant incidence of cancers in animals and their rising incidence with age. Animals rarely exhibit LDL cholesterol levels over 80 mg/dl; some have levels as low as 5–25 mg/dl. Furthermore, the apparent immunity of animals to atherosclerosis is almost certainly not due to an intrinsic resistance of their vessel wall to the atherogenic process — lesions have been induced in virtually every mammalian species by simply raising the total plasma cholesterol level to a sufficiently high value. Thus there is good reason to indict hypercholesterolemia as a centrally important factor in human atherosclerosis.


Foam Cell Oxidative Modification Foam Cell Formation Fatty Streak Smooth Muscle Cell Growth 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Björkhem, I., Henrikkson-Freyschuss, A., Breuer, O., Diczfalusy, U., Berglund, L., and Henriksson, P., 1991, The antioxidant butylated hydroxytoluene protects against atherosclerosis, Arterioscler. Thromb. 11:15–22.CrossRefGoogle Scholar
  2. Brown, M.S. and Goldstein, J.L., 1983, Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis, Ann. Rev. Biochem. 52:223–261.CrossRefGoogle Scholar
  3. Carew, T., Schwenke, D.C., and Steinberg, D., 1987, Antiatherogenic effect of probucol unrelated to it hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit, Proc. Natl. Acad. Sci. USA. 84:7725–7729.CrossRefGoogle Scholar
  4. Daugherty, A., Zweifel, B.S., and Schonfeld, G., 1989, Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbit, Br. J. Pharmacol. 98:612–618.CrossRefGoogle Scholar
  5. Davies, P.F., Reidy, M.A., Goode, T.B., and Bowyer, D.E., 1971, Scanning electron microscopy in the evaluation of endothelial integrity of the fatty lesion in atherosclerosis, Atheroscler. 25:125–130.Google Scholar
  6. Davies, M.J. and Woolf, M., 1990, Atheroma: Atherosclerosis in ischaemic heart disease, in: “The Mechanisms”, Volume I,. Science Press, London.Google Scholar
  7. Gaziano, J.M., Manson, J.E., Ridker, P.M., Buring, J.E., and Hennekens, C.H., 1990, Beta-carotene therapy for chronic stable angina (Abstract), Circulation 82(Suppl. III):201.Google Scholar
  8. Gey, K.F. and Puska, P., 1989, Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology, Ann. N.Y. Acad. Sci. 570:268–82.CrossRefGoogle Scholar
  9. Harats, D., Ben-Nairn, M., Dabach, Y., et al., 1990, Effect of vitamin and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking, Atheroscler. 85:47–54.CrossRefGoogle Scholar
  10. Henriksen, T., Mahoney, E.M., and Steinberg, D., 1981, Enhanced macrophage degradation of low-density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low-density lipoprotein, Proc. Natl. Acad. Sci. USA. 78:6499–6503.CrossRefGoogle Scholar
  11. Khoo, J.C., Miller, E., McLoughlin, P., and Steinberg, D., 1988, Enhanced macrophage uptake of low-density lipoprotein after self-aggregation, Arterioscler. 8:348–358.CrossRefGoogle Scholar
  12. Kita, T., Nagano, Y., Kokode, M., et al., 1987, Probucol prevents the progression of atherosclerosis in Watanabe heritable hvperlipidemic rabbit, an animal model for familial hypercholesterolemia, Proc. Natl. Acad. Sci. USA. 84:5928–5931.CrossRefGoogle Scholar
  13. Krieger, M., Acton, S., Ashkenas, J., Pearson, A., Penman, M., and Resnick, D., 1993, Molecular flypaper, host defense, and atherosclerosis, J. Biol. Chem. 268:4569–4572.Google Scholar
  14. Parthasarathy, S., Young, S.G., Witztum, J.L., Pittman, R.C., and Steinberg, D., 1986, Probucol inhibits oxidative modification of low-density lipoprotein, J. Clin. Invest. 77:641–644.CrossRefGoogle Scholar
  15. Rimm, E.B., Stampfer, M.J., Ascherio, A., Giovannucci, E., Colditz, G.A., and Willett, W.C., 1993, Vitamin E consumption and the risk of coronary disease in men, New Engl. J. Med. 328:1450–1456.CrossRefGoogle Scholar
  16. Ross, R. and Glomset, J.A., 1976, The pathogenesis of atherosclerosis, New Engl. J. Med. 295:369–377; 420-425.CrossRefGoogle Scholar
  17. Ross, R. 1986. The pathogenesis of atherosclerosis — an update, New Engl. J. Med. 314:488–500.CrossRefGoogle Scholar
  18. Sparrow, C.P., Doebber, T.W., Olszewski, J., et al., 1992, Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N.N′-diphenyl-phenylenediamine, J. Clin. Invest. 89:1885–1891.CrossRefGoogle Scholar
  19. Stampfer, M.J., Hennekens, C.H., Manson, J.E., Colditz, G.A., Rosner, B., and Willett, W.C., 1993, Vitamin E consumption and the risk of coronary disease in women, New Engl. J. Med. 328:1444–1449.CrossRefGoogle Scholar
  20. Stary, H.C., 1987, Macrophages, macrophage foam cells, and eccentric intimai thickening in the coronary intima of young children, Atheroscler. 64:91–108.CrossRefGoogle Scholar
  21. Stein, Y., Stein, O., Delplanque, B., Fesmire, J.D., Lee, D.M., and Alaupovic, P., 1989, Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels, Atheroscler. 75:145–155.CrossRefGoogle Scholar
  22. Steinberg, D., 1983. Lipoproteins and atherosclerosis — a look back and a look ahead, Arterioscler. 3:283–301.CrossRefGoogle Scholar
  23. Steinberg, D., 1991, Antioxidants and atherosclerosis: A current assessment, Circulation 84(3): 1420–1425.CrossRefGoogle Scholar
  24. Steinberg, D., 1993, Antioxidant vitamins and coronary heart disease, New Engl. J. Med. 328:1487–1489.CrossRefGoogle Scholar
  25. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L., 1989, Beyond cholesterol, New Engl. J. Med. 320:915–924.CrossRefGoogle Scholar
  26. Steinberg, D. and Witztum, J.L., 1990, Lipoproteins and atherogenesis, Current concepts, JAMA 264:3047–3052.Google Scholar
  27. Steinberg, D. and Workshop Participants, 1992, Antioxidants in the Prevention of Human Atherosclerosis, Summary of the Proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5–6, 1991, Bethesda. Circulation 85(6):2338–2344.CrossRefGoogle Scholar
  28. Verlangieri, A.J. and Bush, M.J., 1992, Effects of d-α-tocopherol supplementation on experimentally induced primate atherosclerosis, J. Amer. Coll. Nutr. 11(2): 131–138.Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Daniel Steinberg
    • 1
  1. 1.Department of MedicineUniversity of California, San DiegoLa JollaUSA

Personalised recommendations